医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aroa Biosurgery Launches Large Format Endoform® to Treat Larger, More Complex Wounds

2020年02月07日 PM08:00
このエントリーをはてなブックマークに追加


 

AUCKLAND, New Zealand

Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a large format version of its Endoform® Natural product.

The largest of Aroa’s wound care products, the 8.5 by 6-inch device has been launched in the United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system.

Aroa Chief Executive, Brian Ward said this large format version of Endoform® Natural addresses the growing need to treat large wounds with a single sheet of their extracellular matrix-based product and provides more options for clinicians.

“We saw a need to offer Healthcare Providers a simple option for larger and often more difficult-to-treat wounds arising from trauma and complications from surgical wounds, or other diseases where healing is impaired. This format is also suitable for wounds such as chronic wounds and venous leg ulcers.

“We are also seeing that Endoform® Natural is increasingly being used in conjunction with negative pressure wound therapy, and this large format will be particularly useful in these treatment applications.”

Aroa intends to make the large format available in a range of global markets as and when regulatory approvals are granted.

“Aroa is committed to having solutions for a wide variety of wounds and wound sizes, and to partnering with clinicians to ensure there are effective solutions for patients presenting with an array of challenging wounds,” says Brian Ward.

About Aroa Biosurgery:

Aroa headquartered in Auckland, New Zealand is a private, venture-funded soft-tissue repair company that develops and manufactures medical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from their Endoform® platform, a novel extracellular matrix biomaterial and distributed in the United States by Appulse and Tela Bio. Aroa strives to improve patient outcomes and provide better healing, every day, everywhere for everybody. www.aroabio.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005031/en/

CONTACT

Further information:

Piet de Jong, For Aroa Communications

piet.dejong@baldwinboyle.com, +64 21 812 766

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease